Book a demo

Chemical intelligence powered by cypris.ai

Semaglutide

18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid · also: Wegovy · Ozempic · Rybelsus · Kayshild · semaglutida · Sermaglutide

FormulaC187H291N45O59
Mol. weight4113.641
PubChem CID56843331
InChIKeyDLSWIYLPEUIQAV-CCUURXOWSA-N
SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
8,537Patents
1,345Research papers1,324 indexed in detail
3,942Patents - last 3 years
835Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Sanofi SA1,540
2Novo Nordisk Fonden449
3SHL Medical AG287
4Pfizer Inc268
5Merck and Co Inc255
6Gilead Sciences Inc233
7C.H. Boehringer Sohn AG and Co KG174
8Bristol Myers Squibb Co111
9Organon and Co87
10Eli Lilly and Co76

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations5,630
2A61PTherapeutic activity (drug indications)5,280
3C07KPeptides2,216
4A61MDevices for introducing media into the body1,933
5C07DHeterocyclic compounds1,891
6C12NMicroorganisms, enzymes608
7G16HDigital health, healthcare informatics313
8C07BGeneral methods of organic chemistry302
9C07CAcyclic and carbocyclic compounds296
10G01NInvestigating / analysing materials275

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Representative patents

The filings that best characterise the patent activity around this compound, most-referenced first.

TitleYearAssigneeCited by
Preparation method of semaglutide201532
Solid synthetic method of semaglutide201423
High-expression semaglutide precursor recombinant engineering bacterium and construction method thereof2021Sihuan Pharmaceutical Holdings Group Ltd18
Semaglutide purifying method201617
Preparation method of semaglutide and intermediate of semaglutide201611

How research activity has moved

Papers published per year for this compound, over the last decade of indexed records.

YearPapers
20164
201735
201858
201972
202080
2021115
2022118
2023195
2024449
2025191

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Ildiko LingvayThe University of Texas Southwestern Medical Center50
2Søren RasmussenNovo Nordisk (Denmark)19
3Melanie J. DaviesUniversity of Leicester18
4Vanita R. ArodaBrigham and Women's Hospital17
5Tina VilsbøllUniversity of Copenhagen16
6Andrei‐Mircea CatarigNovo Nordisk (Denmark)16
7A. Michael LincoffCleveland Clinic Lerner College of Medicine15
8Mark C. PetrieUniversity of Glasgow14
9Sanjiv J. ShahNorthwestern University12
10G. Kees HovinghNovo Nordisk (Denmark)11

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

TitleYearCited byTopic
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes20166787Diabetes Treatment and Management
Once-Weekly Semaglutide in Adults with Overweight or Obesity20214830Diabetes Treatment and Management
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes20232875Diabetes Treatment and Management
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes20212004Diabetes, Cardiovascular Risks, and Lipoproteins
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis20201959Liver Disease Diagnosis and Treatment

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of semaglutide?

Semaglutide has a molecular formula of C187H291N45O59 and a molecular weight of 4113.641 g/mol.

Which organizations hold the most patents related to semaglutide?

Sanofi SA holds the largest patent portfolio with 1540 patents, followed by Novo Nordisk Fonden with 449 patents and SHL Medical AG with 287 patents related to semaglutide.

What are the most common CPC patent classifications for semaglutide patents?

The most frequently used CPC subclasses for semaglutide patents are A61K (5630 patents), A61P (5280 patents), and C07K (2216 patents), reflecting its classification as a pharmaceutical substance and its peptide structure.

Which researcher has published the most papers on semaglutide?

Ildiko Lingvay from The University of Texas Southwestern Medical Center is the most prolific author, with 50 papers on semaglutide-related topics.

How has patent activity around semaglutide changed over time?

Patent activity has grown significantly, rising from 174 patents in 2016 to a peak of 1823 patents in 2024. The last three years (2022-2024) accounted for 4490 of the total 8537 patents, demonstrating accelerating research and development activity.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial